Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 14,977 as of Monday, May 6, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,675 issues advancing vs. 1,221 declining with 157 unchanged. The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 2.36, and Express Scripts ( ESRX), down 1.04. Top gainers within the sector include UnitedHealth Group ( UNH), up 3.0%, Humana ( HUM), up 3.0%, St Jude Medical ( STJ), up 2.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%. TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today: 5. AstraZeneca ( AZN) is one of the companies pushing the Health Care sector lower today. As of noon trading, AstraZeneca is down $0.27 (-0.5%) to $51.76 on light volume Thus far, 377,254 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $51.64-$51.91 after having opened the day at $51.90 as compared to the previous trading day's close of $52.03. AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $64.1 billion and is part of the drugs industry. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 10.1% year to date as of the close of trading on Friday. TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AstraZeneca Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.